Healthcare Apr 25, 2022 09:27 AM (GMT+8) · EqualOcean
Recently, Hefei Tiangang immunopharmaceutical Co., Ltd., an invisible Unicorn enterprise in the field of tumor immunotherapy, announced the completion of a pre-A round of financing of hundreds of millions of yuan. This round of financing is jointly led by Zhongke Chuangxing and chuanggu capital, followed by Hefei industrial investment, Yifeng capital, Tiantu investment, Guoyuan innovation investment and other well-known investment institutions. The raised funds will be used to promote the R & D and registration of multiple product pipelines for tumor immunotherapy. Hefei Tiangang immune drugs Co., Ltd., established in 2020, is a high-tech company focusing on the development of innovative immune drugs at the source. The company's R & D team discovered and verified multiple NK cell immune test points earlier in the world. The company has planned a series of technologies and products, covering: immune checkpoint inhibitors; Bifunctional / multifunctional antibody analogues; Targeted antibody drugs; Immunomodulator, etc.

This text is a result of machine translation.